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Abstract Neural tube defects (NTDs) are the second most
common group of serious birth defects. Although folic acid
has been shown to reduce effectively the risk of NTDs and
measures have been taken to increase the awareness,
knowledge, and consumption of folic acid, the full potential
of folic acid to reduce the risk of NTDs has not been
realized in most countries. To understand the economic
burden of NTDs and the economic impact of preventing
NTDs with folic acid, a systematic review was performed
on relevant studies. A total of 14 cost of illness studies and
10 economic evaluations on prevention of NTDs with folic
acid were identified. Consistent findings were reported
across all of the cost of illness studies. The lifetime direct
medical cost for patients with NTDs is significant, with the
majority of cost being for inpatient care, for treatment at
initial diagnosis in childhood, and for comorbidities in adult
life. The lifetime indirect cost for patients with spina bifida
is even greater due to increased morbidity and premature
mortality. Caregiver time costs are also significant. The
results from the economic evaluations demonstrate that
folic acid fortification in food and preconception folic acid
consumption are cost-effective ways to reduce the inci-
dence and prevalence of NTDs. This review highlights the
significant cost burden that NTDs pose to healthcare
systems, various healthcare payers, and society and
concludes that the benefits of prevention of NTDs with
folic acid far outweigh the cost. Further intervention with
folic acid is justified in countries where the full potential of
folic acid to reduce the risk of NTDs has not been realized.
Keywords Neural tube defects.Spina bifida.Economic
burden.Cost.Folic acid.Prevention
Introduction
Neural tube defects (NTDs) are the second most common
group of serious birth defects. NTDs result from failure of
the neural tube to close properly, approximately 28 days
postconception. Typically, this occurs before the woman
knows that she is pregnant [7, 38]. Despite the identified
association between the achievement of adequate folate
level at time of conception and a risk reduction of NTDs,
NTDs have a complex and imperfectly understood aetiol-
ogy in which both genetic and environmental factors appear
to be involved [7].
Two of the most common NTDs are spina bifida and
anencephaly. Spina bifida results from failure of fusion of
the posterior (caudal) neural tube, whereas anencephaly
results from failure of fusion of the anterior (cranial) neural
tube. Anencephaly is fatal; many children with anencephaly
are stillborn or die shortly after birth. Fifty percent have a
life expectancy of between a few minutes and 1 day, and
25% only live up to 10 days [29]. Children with spina
bifida have a high probability of lifelong physical and
mental handicap, and only a minority of these children are
able to function independently as adults [41]. Due to
advances in medical technology, the life expectancy of
patients with spina bifida is rising annually, with 85% to
90% of children born with the disease surviving into
adulthood [46].
Patients with NTDs regularly have problems related to
hydrocephalus, neurogenic bladder, kidney involvement,
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sequences. These complications can cause severe disability,
which add significant burden to patients with NTDs and
their families.
Each year, 300,000 to 400,000 infants worldwide are
born with spina bifida and anencephaly [16]. Approximately
4,500 pregnancies every year in Europe result in a baby or
foetus affected by an NTD, and in the USA, 2,500 live births
a r ea f f e c t e db yN T D se a c hy e a r[ 51]. In China, 100,000
infants are born annually with NTDs [7].
Treatment for spina bifida includes surgery, medication,
and physiotherapy. Surgery to close the newborn’s spinal
opening is generally performed within 24 h after birth to
minimize the risk of infection and to preserve existing
function in the spinal cord. However, regular monitoring,
ongoing therapy, and medical and/or surgical treatments are
often necessary to prevent and manage complications
throughout the individual’s life. Although many advances
have been made in the treatment of spina bifida, resulting in
increased life expectancy and improved quality of life for
individuals with the disease, no treatment exists that will
completely eliminate the serious disability or premature
mortality associated with it. For these reasons, reducing the
risk of NTDs is an important goal.
Most cases of anencephaly and spina bifida can be
detected through prenatal screening methods such as
second trimester maternal serum alpha-fetoprotein screen-
ing and foetal ultrasound scanning [33]. However, parents
face great distress at the diagnosis of an NTD, confronting
either the grief of a termination or stillbirth or the extensive
emotional and financial challenges of caring for a child
with NTD [32].
Folic acid has been shown to reduce effectively the risk
of NTDs in 1990s [5], and this is supported by the evidence
from recent systematic reviews on folic acid for the
prevention of NTDs in both high- and low-income
countries [6, 52]. Although not all cases of NTDs can be
prevented by increasing the intake of folic acid due to a
‘floor effect’ [26], studies have suggested that 50% to 70%
of cases could be prevented by the appropriate consumption
of folic acid before conception and during early pregnancy
[7]. In 1992, the US Public Health Service recommended
that all women capable of becoming pregnant consume
0.4 mg (or 400 μg) of folic acid daily to reduce their risk
for having a pregnancy affected by NTDs [10]. In 1998, the
US Food and Drug Administration mandated that folic acid
be added to cereal grain products, and a number of media
campaigns, health advisory groups [11], and worldwide
public health campaigns have been launched to increase the
awareness, knowledge, and consumption of folic acid. As a
result, the incidence and prevalence of NTDs have declined
and stabilized in many countries [9, 12, 13, 15, 20, 21, 27,
35, 36, 42, 54]. While food fortification with folic acid is
well established in the USA, Canada, and Chile, in Europe,
the discussion, including what is the optimal approach, is
still ongoing. Moreover, racial/ethnic disparities and
socioeconomic and educational issues in the consumption
of folic acid persist, and differences of supplement use
by age exist [37]. Therefore, the full potential of folic acid
to reduce the risk of NTDs has not yet been realized, and
preventable NTDs continue to occur.
Patients with NTDs are at risk of psychosocial problems
and have acute, lifelong disabilities, which require a
lifetime of medical care [19, 55]. Cost of illness studies
attempts to quantify the economic burden of a disease and
estimate all the costs associated with a particular disease.
These studies provide information on the economic burden
to society or to a specific stakeholder such as the healthcare
payer or the patient. Economic evaluation studies evaluate
whether the effectiveness or benefit of intervention is worth
the cost of implementing the intervention. These studies
provide information for decision makers to determine the
best way of allocating scarce healthcare resources to ensure
a given population receives optimal healthcare.
This paper summarizes the economic evidence from a
systematic review that was conducted to understand the
humanistic and economic burden of NTDs to healthcare
systems, patients, caregivers, and society. While humanistic
patient-reported outcome and caregiver burden are focuses
of other papers, the objective of this paper is to gain greater
insight into the economic burden of NTDs both on healthcare
systems and on wider society and to understand the cost-
effectiveness of folic acid for the prevention of NTDs.
Methods
A literature review was conducted using a standard
systematic approach [14]. To identify relevant studies
associated with costs of NTDs and economic evaluations
of folic acid for the prevention of NTDs, electronic
databases (PUBMED, PsycINFO, and Embase) were
searched for material dating from January 1976 to October
2010, using the following search terms:
○ Neural tube defects OR NTDs OR spina bifida OR
anencephaly OR meningocele AND
○ Cost OR economic OR financial burden/impact of illness/
disease OR resource use OR hospitalization OR
○ Economic evaluation OR cost analysis OR cost effective-
ness OR CEA OR cost minimisation OR CMA OR cost
consequence OR CCA OR cost utility OR CUA OR cost
benefit OR CBA OR cost savings OR patient preferences
AND
○ Folic acid OR folate OR vitamin supplements OR food
fortifi* OR enriched grain
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Centre for Review and Dissemination databases (NHS
Economic Evaluation Database and Health Technology
Assessment (HTA)) were also searched in addition to the
websites of the major HTA bodies (such as the International
Network of Agencies for Health Technology Assessment,
National Institute for Health and Clinical Excellence, and
Scottish Medicines Consortium in the UK, Institute for
Quality and Efficiency in Health Care in Germany, Pharma-
ceutical Benefits Advisory Committee in Australia, and
Canadian Agency for Drugs and Technologies in Health in
Canada). The search was limited to English language articles.
Studies identified for inclusion in the review were cost
of illness studies reporting resource use and costs associ-
ated with NTDs and complications, and economic evalua-
tions estimating both the costs and effects of prevention of
NTDs with folic acid. Data were extracted by one
researcherusingastructureddataextractionformandchecked
by a second researcher. The quality of studies included in the
review was assessed using published checklists [17, 39].
All costs have been inflated and converted from local
currencies to 2011 Euro (€)u s i n gt h eC o n s u m e rP r i c e
Index (CPI) inflation calculators (http://www.bls.gov/
data/inflation_calculator.htm, http://www.rba.gov.au/cal
culator/annualDecimal.html and http://www.rbnz.govt.nz/
statistics/0135595.html) and currency converter at the
exchange rate on 26 April 2011 (i.e. $1=€0.6856, $AU1=
€0.7363 and $NZ1=€0.5427) (http://www.foreign-curren
cy-uk.com/currency_converter.asp). Actual costs reported
in different studies are presented in the brackets.
Moreover, the cost per patient was calculated where
possible in order to compare the different studies and
their varying sample sizes. Where costs have been
converted into Euro from other currencies, these costs
should only be used as a guide because official exchange
rates do not adequately reflect the comparative purchas-
ing power of the local currencies in their own markets
[17].
Results
Literature search results
Fourteencostofillnessstudies(12fromtheUSA,1eachfrom
Canada and Spain) and 10 economic evaluations on preven-
tion with folic acid (4 from the USA, 2 from both Chile and
the Netherlands, 1 each from Australia/New Zealand and
South Africa) were identified for this review (Fig. 1).
The quality of the cost of illness studies was generally
poor. This was largely due to the limited range of costs that
were included in these studies and lack of any sensitivity
analyses to assess the robustness of results. However,
despite these limitations, the overarching results from these
studies are consistent.
Overall, the quality of the economic evaluations was
higher. Most of them were carried out using standard and
recommended methodology. However, there were wide
differences in the way that ‘benefits’ were measured across
the studies such that it was not appropriate to make
comparisons between studies.
Economic burden of NTDs
Table 1 describes the range of costs that were included in
each of the cost of illness studies. The majority of studies
included the medical costs of NTDs, and seven focused
solely on these costs. These are costs that are borne by
healthcare payers such as health insurance programmes,
and include factors such as drugs and hospitalizations
both for managing NTDs directly and for managing
comorbidities. The studies by Waitzman et al. [49, 50]
are more inclusive and take into account costs associated
with development services and special education for
individuals living with NTDs. These types of costs are
often described as direct nonmedical costs. Broader costs
such as lost work time, caregiver costs, and costs due to
premature loss of life were considered in the studies by
Waitzman et al. [49, 50], Lipscomb et al. [34] and Tilford
et al. [47, 48]. These are typically referred to as indirect
costs. The study by Young [53] only reported resource
use of adult patients with spina bifida in Canada without
cost information.
Annual direct medical cost per patient was estimated to
be €42,943 ($51,574 in 2003$) for NTD [43] and between
€11,728 ($11,061 in 1993$) to €54,270 ($65,177 in 2003$)
for spina bifida [28, 40, 43] in the USA. In Spain, the
Social Security system spent direct medical costs of
€3,825,037 ($2,953,138 in 1988$) per year for the care of
patients with spina bifida [3], representing approximately
€3,541 ($2,734 in 1988$) per person per year.
4,456 titles/abstracts located 
143 abstracts selected for assessment  
(economic papers only) 
62 full papers retrieved for more detailed assessment 
14 cost of illness studies   10 economic evaluations of folic acid 
1
st pass against inclusion/exclusion criteria 
2
nd pass against inclusion/exclusion criteria 
Fig. 1 Selection of the studies reviewed
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References Country Direct medical costs Direct nonmedical costs Caregiver time costs Indirect costs
Lipscomb 1986
[34]
USA ––Average reductions of 14 h per
week in paid work time for
mothers and 5 h per week for
fathers
–
Harris et al.
1990 [24]
USA Skin breakdown in
myeloeningocele: €2,466
(1,763 in 1986$)
–––
Bea et al. 1994
[3]
Spain Myeloeningocele: €3,541
(2,734 in 1988$)
–––
Waitzman et al.
1996 [50]
USA SB: age 0–1: €33,213 (34,013
in 1996$); age 2–4: €14,573
(14,924 in 1996$); age 5–17:
€12,897 (13,208 in 1996$);
age 18+: €4,095(4,194
in 1996$)
SB: total per capita lifetime
cost for development and
special education
– Average lifetime
cost per case
of SB
Kinsman et al.
1996 [31]
USA All comorbidity in SB: €4,873
(4,462 in 1992$)
–––
Ireys et al. 1997
[28]
USA SB: €11,728 (11,061 in 1993$) –––
Tilford et al.
2001 [48]
USA ––Caregiver time costs for a case
of SB: €112,901 to €135,743
($164,675 to $197,991, price
year not clear)
–
Waitzman et al.
2004 [49]
USA Average lifetime cost per case
of SB
Average lifetime cost per case
of SB for development and
special education
– Average lifetime
cost per case
of SB
Ouyang et al.
2007 [40]
USA SB: €13,248 (15,911 in 2003$) –––
Robbins et al.
2007 [43]
USA NTD: €42,943 (51,574 in 2003
$); SB: €54,270 (65,177 in
2003$); Anencephaly: €3,131
(3,760 in 2003$);
Encephalocele: €37,509
(45,047 in 2003$)
–––
Armour et al.
2009 [1]
USA People with SB treated for
urinary tract infection—an
ambulatory care sensitive
condition: average Medical
Care expenditure for
hospitalization €8,274 and for
ambulatory care €370 (9,300
and 416 in 2000$,
respectively); patient out-of-
pocket for hospitalization
€623 and €75 for ambulatory
care (700 and 84 in 2000$,
respectively)
–––
Tilford et al.
2009 [47]
USA ––Caregivers of children with SB
worked an annual average of
7.5 to 11.3 h less per week
depending on the disability
severity. This translated into
lifetime costs of €113,910
(133,755 in 2002$) using a
3% discount rate and an age-
and sex-adjusted earnings
profile
–
Bamer et al.
2010 [2]
USA – Average annual Medicaid cost
of AT was €347 ($494, price
year not clear) per enrolee
with SB and ATaccounted for
––
1394 Eur J Pediatr (2011) 170:1391–1400A significant proportion of the cost burden occurs during
childhood. For example, in the USA, total hospital charges
for new born infants with NTDs amounted to €62 million
for spina bifida, €1 million for anencephaly and €9 million
for encephalocele ($74 million, $1 million and $11 million
in 2003$, respectively) [43]. More specifically, the Medic-
aid in Washington State spent €2 million ($2.1 million in
1993$) on children with spina bifida in 1993, and average
payments for children with spina bifida were 11.6 times
higher than the average payment for all children in the
state’s Medicaid programme [28].
While children and adolescents with spina bifida incur
medical expenditures several times higher than children and
adolescents without the disease [28, 49], young adults with
the condition also continue to be high users of medical care
[53]. Adults account for 67% of persons with spina bifida
and 66% of medical expenditures associated with spina
bifida in USA [40]. At any age, individuals with spina
bifida incur higher medical expenditures than those with-
out, and costs continue to be high throughout adulthood
[40] (Fig. 2).
Almost half of the hospital admissions for adults with
spina bifida are due to secondary conditions (such as
serious urologic infections, renal calculi, pressure ulcers,
and osteomyelitis), and the financial costs of these
admissions are substantial [31]. The annual direct medical
cost per patient for the treatment of spina bifida comorbid-
ities in the USA ranged between €2,466 [24] and €4,873
[31]. In Canada, Young [53] reported that hospital
admission rate for adults with chronic and complex
physical disabilities of childhood including spina bifida is
nine times that of the general population, and adult patients
with spina bifida are regular users of outpatient and
inpatient services (Table 1).
Individuals with spina bifida often require walking aids
and wheelchairs for functional mobility. In the USA in any
given year, on average, 33% of individuals with spina bifida
made claims from Medicaid for some type of mobility-related
assistive technology, including wheelchair-related costs,
orthotics and prosthetics, ambulatory aids, and communica-
tion and hearing aids [2]. Annually, these claims accounted
for €297,704 (price year not reported), which represents
approximately 3.3% of all reimbursement by Medicaid for
all medical care for these individuals [2].
Five studies, which looked beyond the direct costs
incurred by the healthcare system when evaluating the
burden of NTDs, suggest that indirect costs of spina bifida
are substantial. Tilford et al. found [48] a substantial impact
of caring for a child with spina bifida on labour force
participation, with participation rates 21% to 27% lower
than those individuals in the control group (population from
the Current Population Survey covering the state of
Arkansas). Caregivers of children with spina bifida worked
an annual average of 7.5 to 11.3 h less per week depending
on disability severity. Differences in work hours by care-
givers of children with spina bifida translated into lifetime
Table 1 (continued)
References Country Direct medical costs Direct nonmedical costs Caregiver time costs Indirect costs
3.3% of all Medicaid costs for
them. AT-related costs were
highest for those aged 0–
15 years and lowest for those
aged 16–25 years
Young 2005
[53]
Canada Only reported resource use: over 95% of adult patients with SB were seen by a physician each year; Outpatient
physician visits: 8.99 office appoints and 0.47 emergency department visits per person per year; Inpatient admission:
one admission for each patient every 5.7 years.
AT assistive technology, NTD neural tube defect, SB spina bifida
Source: Based on Ouyang et al 2007 [40]
Fig. 2 Annual per patient
medical expenditures in 2011€:
persons with vs. without
spina bifida
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1396 Eur J Pediatr (2011) 170:1391–1400costs of €95,186 ($111,755 in 2002$) using a 3% discount
rate and an age- and sex-adjusted earnings profile.
Lipscomb et al. estimated an average reduction of paid
work time of 14 h per week for mothers and 5 h per week
for fathers of children with spina bifida [34]. The estimated
caregiver time costs to care for a children with spina bifida
until age 25 ranges from €142,477 to €171,303 ($164,675
to $197,991 in 2001$) depending on the discount rates used
in estimating the present value of future costs [47].
Total lifetime costs for patients with spina bifida
amounted to €528,425 ($620,484 in 2002$) [50]. Just
37.1% of the total was attributable to direct medical costs
(€187,859 ($220,560)), with the costs associated with
special education and development services accounting for
6.5% (€35,204 ($41,337)) and 0.3% (€1,732 ($2,034)),
respectively. The remaining 56.1% of the total were indirect
costs (€303,690 ($356,553)), of which €117,613 ($138,086)
wereduetoincreasedmorbidityand€186,085($218,477)due
to premature mortality [50].
Economic impact of preventing NTDs with folic acid
Although there is a limited research in this field, the
available evidence indicates that the economic burden of
NTDs is substantial. A reduction in the incidence and
prevalence of NTDs would reduce this economic burden.
Very few studies have evaluated the cost-effectiveness of
prevention strategies for NTDs. In the 10 identified
economic evaluation studies of folic acid for the prevention
of NTDs, 8 evaluated the cost-effectiveness of folic acid
fortification in foods [4, 18, 23, 25, 30, 36, 44, 45], and 2
evaluated the cost-effectiveness of periconceptional supple-
mentation of folic acid [22, 41] (Table 2). Nine of the
studies included direct medical costs only; indirect costs
and benefits were included in only one study [44].
While it is inappropriate to compare results across the
identified studies due to the differences in the measures of
benefits, each individual study suggested that prevention
with folic acid is cost-effective, i.e. that the benefits
outweighed the cost (except for mandatory fortification
for New Zealand).
In the eight economic evaluations on folic acid food
fortification identified by this literature review, all concluded
that fortification of food with folic acid is a cost-effective
method for reducing the incidence of NTDs. As shown in
Table 2, the benefit–cost ratio, a measure of cost–benefit,
ranged from 4.3 to 1 in USA [44], 11.8 to 1 in Chile [25, 36]
to 30 to 1 in South Africa [45], suggesting that the economic
benefit from the prevention of NTDs greatly exceeded the
cost of folic acid fortification in these countries. The cost per
NTD averted, a measure of cost-effectiveness, was estimated
to range from €1,068 in Chile [25, 36]t o€103,502 ($65,000
to $92,000 in 1991$) in the USA [44]. The cost savings
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Netherlands [30]. The cost per disability-adjusted quality
of life (DALY) averted was estimated to be close to €80 in
Chile [25, 36]a n d€7,518 for voluntary fortification in
Australia and New Zealand. The cost per quality-adjusted
life year (QALY), a measure of cost-utility, was estimated
to be €854 in the Netherlands [30].
Similarly, economic evaluations suggest that periconcep-
tional supplementation of folic acid is a good use of
healthcare resources and justifies further promotion of the
use of folic acid supplementation prior to pregnancy. The
cost per life year gained from periconceptional supplemen-
tation of folic acid was estimated to be €2,108 (NLG 3,900
in 2000 price) in the Netherlands [41]. In the USA, the cost
per QALY gained from the NTD recurrence prevention
programmes promoting folic acid supplementation ranged
from €12,240 to €45,963 ($14,700 to $55,200 in 2003$),
which led the authors to conclude that the NTD recurrence
prevention programme provided value for the money spent
relative to other public health interventions [22].
In all the countries where cost–benefit of folic acid for
the prevention of NTDs was evaluated, several millions to
hundreds of millions of Euros (or dollars) of net benefit or
cost savings were estimated. These results strongly support
the continuation of folic acid for the prevention of NTDs,
especially in countries with NTD prevalence far above the
observed floor for folic acid-preventable NTD [26].
Discussion
There are some limitations to this review which deserve
comment. Given the gravity of NTDs, we found surpris-
ingly few studies that evaluated the economic burden of the
disease and the economic impact of prevention with folic
acid. These studies reported findings from a limited number
of countries (mainly the USA) and focused on spina bifida
over other NTDs. In addition, most of the studies were based
on data collected more than 10 years ago and therefore may
not reflect techniques currently used for prenatal diagnosis
and interruption of pregnancy and management of NTDs [8].
The quality of the cost of illness studies was generally poor,
with few studies addressing all important aspects of cost of
illness and uncertainties around the estimation of costs.
Methodological differences limited comparisons between
studies. Moreover, while the economic evaluations were of
good quality, comparisons between studies could not be
made because the measures of benefit differed.
Despite these limitations, consistent findings were
reported across all studies. NTDs represent a high cost per
patient to healthcare payer and society. Key cost drivers are
the inpatient days at initial diagnosis in childhood and, later
in life, treatment of comorbidities in survivors. The lifetime
costs are significant, as patients require ongoing care
throughout their lives. Patients with NTDs also require
other forms of support that result in direct nonmedical
costs, such as special education, developmental services
and mobility-related assistive devices. Caregivers of chil-
dren with spina bifida are impacted by economic factors
such as a reduction of paid work time. In addition, there are
significant indirect costs associated with NTDs due to the
reduced productivity of the patients themselves. These
results demonstrate the significant lifetime cost burden of
NTDs to healthcare systems, various healthcare payers,
caregivers, and society in general.
As caregiver time costs and indirect costs associated
with morbidity and premature death of individuals with
NTDs are significant, they should be included in economic
evaluations of interventions to prevent NTDs. However, a
few of the available economic evaluations of folic acid have
considered caregiver time costs and indirect costs. The
review found that even without considering the significant
indirect costs associated with NTDs, folic acid fortification in
food and preconception folic acid consumption are still cost-
effective ways to reduce the incidence and prevalence of
NTDs. However, the full potential of folic acid to reduce the
risk of NTDs has not been realized in many countries,
suggesting that more can be done to reduce greatly the
incidence of the condition and its associated economic burden.
Further research is required to understand fully the
economic impact of NTDs. Studies in a wider range of
countries are needed, as differences in the healthcare system
structure and in the management of NTDs across countries
limit the generalizability of the findings from the studies
reported here to other countries. In order to understand fully
the burden of this disease, a broader range of costs should
be measured. Outpatient care costs and broader societal costs
such as nonmedical costs and the indirect costs associated
with lost productivity and premature death would be of
particular interest, given the limited data currently available.
Moreover, in order to compare the cost-effectiveness of
alternative prevention strategies, future studies should use a
standard approach to the measurement of effectiveness or
benefit of the prevention strategies. The use of a generic
measure of benefit, for example quality-adjusted life years
saved, would enable those who fund healthcare for a defined
population to assess the value of alternative prevention
options for NTDs and therefore fund the option that provides
the maximal benefit within the funds available.
Conclusion
This review has highlighted the significant cost burden that
NTDs pose to healthcare systems, various healthcare
payers, and wider society, concluding that the benefits of
1398 Eur J Pediatr (2011) 170:1391–1400preventing this condition with folic acid outweigh the costs
of such initiatives. In countries where the full potential of
folic acid to reduce the risk of NTDs has not been realized,
further intervention with folic acid is justified.
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